Aurobindo Pharma receives USFDA approval for Polymyxin B for Injection

05 Apr 2016 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Polymyxin B for Injection USP, 500,000 units/vial. This product is expected to be launched in Q2 FY16-17. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Polymyxin B for Injection USP, 500,000 units/vial of Eurohealth International Sarl.

Polymyxin B for Injection is an Anti-Infective used in the treatment of infections of the urinary tract, meninges, bloodstream and eye caused by susceptible strains of Pseudomonas aeruginosa. According to IMS, the approved product has an estimated market size of $7.6 million for the twelve months ending February 2016.

This is the 31st ANDA (including two tentative approvals) to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable products. Aurobindo now has a total of 252 ANDA approvals (216 Final approvals including 10 from Aurolife Pharma LLC and 36 tentative approvals) from USFDA.



Aurobindo Pharma Share Price

1160.85 -6.35 (-0.54%)
20-Jan-2026 12:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.70
Dr. Reddys Lab 1184.30
Cipla 1378.30
Zydus Lifesciences 875.05
Lupin 2163.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×